174 related articles for article (PubMed ID: 22810479)
41. Increased expression of annexin A1 is correlated with K-ras mutation in colorectal cancer.
Su N; Xu XY; Chen H; Gao WC; Ruan CP; Wang Q; Sun YP
Tohoku J Exp Med; 2010 Dec; 222(4):243-50. PubMed ID: 21127395
[TBL] [Abstract][Full Text] [Related]
42. K-Ras mutation detection in liquid biopsy and tumor tissue as prognostic biomarker in patients with pancreatic cancer: a systematic review with meta-analysis.
Li T; Zheng Y; Sun H; Zhuang R; Liu J; Liu T; Cai W
Med Oncol; 2016 Jul; 33(7):61. PubMed ID: 27225938
[TBL] [Abstract][Full Text] [Related]
43. Discrepancies between the K-ras mutational status of primary colorectal cancers and corresponding liver metastases are found in codon 13.
Kawamata H; Yamashita K; Kojo K; Ushiku H; Ooki A; Watanabe M
Genomics; 2015 Aug; 106(2):71-5. PubMed ID: 26026309
[TBL] [Abstract][Full Text] [Related]
44. Combined assessment of epidermal [corrected] growth factor receptor dual color in situ hybridization and immunohistochemistry with downstream gene mutations in prediction of response to the anti-EGFR therapy for patients with metastatic colorectal cancer.
Takahashi N; Yamada Y; Taniguchi H; Honma Y; Iwasa S; Kato K; Hamaguchi T; Shimada Y
Arch Med Res; 2014 Jul; 45(5):366-74. PubMed ID: 24830936
[TBL] [Abstract][Full Text] [Related]
45. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
[TBL] [Abstract][Full Text] [Related]
46. K-ras mutation detection in colorectal cancer using the Pyrosequencing technique.
Poehlmann A; Kuester D; Meyer F; Lippert H; Roessner A; Schneider-Stock R
Pathol Res Pract; 2007; 203(7):489-97. PubMed ID: 17629419
[TBL] [Abstract][Full Text] [Related]
47. Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer.
Ogura T; Yamao K; Hara K; Mizuno N; Hijioka S; Imaoka H; Sawaki A; Niwa Y; Tajika M; Kondo S; Tanaka T; Shimizu Y; Bhatia V; Higuchi K; Hosoda W; Yatabe Y
J Gastroenterol; 2013 May; 48(5):640-6. PubMed ID: 22983505
[TBL] [Abstract][Full Text] [Related]
48. Association of folate intake, dietary habits, smoking and COX-2 promotor -765G>C polymorphism with K-ras mutation in patients with colorectal cancer.
Kamal MM; Youssef OZ; Lotfy AN; Elsaed ET; Fawzy MM
J Egypt Natl Canc Inst; 2012 Sep; 24(3):115-22. PubMed ID: 22929917
[TBL] [Abstract][Full Text] [Related]
49. [Identification of K-RAS mutations in colorectal cancer patients in Israel].
Segal G; Liebermann N; Klang S; Siegelmann-Daniel N; Beit-Or A; Klien B; Shoushan-Gutman L
Harefuah; 2011 May; 150(5):447-50, 491. PubMed ID: 21678640
[TBL] [Abstract][Full Text] [Related]
50. Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan.
Scartozzi M; Mandolesi A; Giampieri R; Pierantoni C; Loupakis F; Zaniboni A; Galizia E; Giustini L; Silva RR; Bisonni R; Berardi R; Biagetti S; Menzo S; Falcone A; Bearzi I; Cascinu S
Int J Cancer; 2010 Oct; 127(8):1941-7. PubMed ID: 20099280
[TBL] [Abstract][Full Text] [Related]
51. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.
Kern JA; Slebos RJ; Top B; Rodenhuis S; Lager D; Robinson RA; Weiner D; Schwartz DA
J Clin Invest; 1994 Feb; 93(2):516-20. PubMed ID: 7906694
[TBL] [Abstract][Full Text] [Related]
52. Prognostic value of circulating KRAS2 gene mutations in colorectal cancer with distant metastases.
Trevisiol C; Di Fabio F; Nascimbeni R; Peloso L; Salbe C; Ferruzzi E; Salerni B; Gion M
Int J Biol Markers; 2006; 21(4):223-8. PubMed ID: 17177160
[TBL] [Abstract][Full Text] [Related]
53. [Correlation analysis between abundance of K-ras mutation in plasma free DNA and its correlation with clinical outcome and prognosis in patients with metastatic colorectal cancer].
Bai YQ; Liu XJ; Wang Y; Ge FJ; Zhao CH; Fu YL; Lin L; Xu JM
Zhonghua Zhong Liu Za Zhi; 2013 Sep; 35(9):666-71. PubMed ID: 24332053
[TBL] [Abstract][Full Text] [Related]
54. K-ras mutation status correlates with the expression of VEGFR1, VEGFR2, and PDGFRalpha in colorectal cancer.
Schimanski CC; Zimmermann T; Schmidtmann I; Gockel I; Lang H; Galle PR; Moehler M; Berger MR
Int J Colorectal Dis; 2010 Feb; 25(2):181-6. PubMed ID: 19936766
[TBL] [Abstract][Full Text] [Related]
55. Integrating RAS status into prognostic signatures for adenocarcinomas of the lung.
Starmans MH; Pintilie M; Chan-Seng-Yue M; Moon NC; Haider S; Nguyen F; Lau SK; Liu N; Kasprzyk A; Wouters BG; Der SD; Shepherd FA; Jurisica I; Penn LZ; Tsao MS; Lambin P; Boutros PC
Clin Cancer Res; 2015 Mar; 21(6):1477-86. PubMed ID: 25609067
[TBL] [Abstract][Full Text] [Related]
56. Mutations of p53 and K-ras correlate TF expression in human colorectal carcinomas: TF downregulation as a marker of poor prognosis.
Rao B; Gao Y; Huang J; Gao X; Fu X; Huang M; Yao J; Wang J; Li W; Zhang J; Liu H; Wang L; Wang J
Int J Colorectal Dis; 2011 May; 26(5):593-601. PubMed ID: 21404058
[TBL] [Abstract][Full Text] [Related]
57. Prognostic value of K-ras mutations and allelic imbalance on chromosome 18q in patients with resected colorectal cancer.
Font A; Abad A; Monzó M; Sanchez JJ; Guillot M; Manzano JL; Piñol M; Ojanguren I; Rosell R
Dis Colon Rectum; 2001 Apr; 44(4):549-57. PubMed ID: 11330582
[TBL] [Abstract][Full Text] [Related]
58. Different types of K-Ras mutations are conversely associated with overall survival in patients with colorectal cancer.
Winder T; Mündlein A; Rhomberg S; Dirschmid K; Hartmann BL; Knauer M; Drexel H; Wenzl E; De Vries A; Lang A
Oncol Rep; 2009 May; 21(5):1283-7. PubMed ID: 19360305
[TBL] [Abstract][Full Text] [Related]
59. K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases.
Huncharek M; Muscat J; Geschwind JF
Carcinogenesis; 1999 Aug; 20(8):1507-10. PubMed ID: 10426799
[TBL] [Abstract][Full Text] [Related]
60. Worst outcomes according to RAS mutation variants: an analysis in patients with metastatic colorectal adenocarcinoma.
Usón PLS; Bugano DDG; Moura F; Carvalho RS; Maluf FC
J BUON; 2018; 23(4):925-935. PubMed ID: 30358195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
